文献速递眼底病与葡萄膜炎

从阿瓦斯汀与OCT中汲取的经验教训:LXXV Edward Jackson纪念讲座

Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture.
PubMed 文献 · Am J Ophthalmol · 2019-03-07

该讲座回顾性总结了OCT与VEGF抑制剂(尤其玻璃体腔贝伐珠单抗)在渗出性年龄相关性黄斑变性(AMD)治疗中的协同获益与成本节约。OCT作为无创影像清晰显示黄斑积液及抗VEGF治疗后的积液消退与视力改善,临床医生据此采用OCT引导的治疗方案而非固定间隔给药。

要点

  • OCT无创显示渗出性AMD黄斑积液及抗VEGF治疗后积液消退与视力改善。
  • 临床采用OCT引导的抗VEGF给药方案,而非临床试验中的固定间隔给药。
  • 玻璃体腔贝伐珠单抗因可及性、低成本与疗效证据在全球迅速推广。

核心结论

  • OCT引导治疗与玻璃体腔贝伐珠单抗的快速采用在全球范围内防止了渗出性和新生血管性眼病导致的失明,同时为医疗支付方和患者节省了数十亿美元。

研究设计与样本

  • 本文为回顾性文献综述与个人观点,非前瞻性研究,未报告样本量。

主要发现

  • 第一台临床可用的OCT仪器问世与后来称为雷珠单抗的药物的早期临床试验同期。
  • OCT无创显示渗出性AMD相关黄斑积液及抗VEGF治疗消退积液并伴随视力改善的能力。
  • 临床医生采用OCT成像作为抗VEGF药物给药依据,而非临床试验标准及获批后行业推荐的固定间隔给药。
  • 静脉贝伐珠单抗治疗渗出性AMD获得与雷珠单抗相似的视力与OCT改善,该观察于2005年促成玻璃体腔贝伐珠单抗的使用。
  • 雷珠单抗与贝伐珠单抗包装摩尔浓度相似,眼内注射相似体积可产生相似抗VEGF活性。

关键数值与推荐

  • 贝伐珠单抗在美国的治疗成本为每1 mg 5.50美元。

临床怎么用

  • 临床可采用OCT成像作为抗VEGF药物治疗渗出性AMD的给药依据。
  • 玻璃体腔贝伐珠单抗可用于治疗VEGF驱动的眼病。

局限性

  • 本文为回顾性文献综述与个人观点,非系统评价或前瞻性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the synergistic benefits and cost savings from the use of optical coherence tomography (OCT) and vascular endothelial growth factor (VEGF) inhibitors, particularly intravitreal bevacizumab, in the treatment of exudative age-related macular degeneration (AMD). DESIGN: Retrospective literature review and personal perspective. METHODS: Retrospective literature review and personal perspective. RESULTS: The introduction of the first clinically useful OCT instrument coincided with early-phase clinical trials of a drug that would become known as ranibizumab. OCT provided a noninvasive imaging strategy that unambiguously showed the macular fluid associated with exudative AMD and the ability of anti-VEGF therapy to resolve this fluid with concomitant visual acuity improvement. Clinicians came to embrace the use of OCT imaging as the basis for dosing with anti-VEGF drugs, rather than the fixed-interval dosing that was the standard in clinical trials and recommended by industry after approval. But, before ranibizumab was approved for the treatment of exudative AMD, intravenous bevacizumab was approved to treat cancer. Both drugs shared a common molecular lineage, and this led to a clinical trial using intravenous bevacizumab for the treatment of exudative AMD. Intravenous bevacizumab resulted in visual acuity and OCT improvements similar to ranibizumab, and this observation soon led to the intravitreal use of bevacizumab in 2005. Fortuitously, both ranibizumab and bevacizumab were packaged at similar molar concentrations, so similar volumes of both drugs when injected into an eye would result in similar anti-VEGF activity. With ranibizumab not yet commercially available, intravitreal bevacizumab rapidly became adopted worldwide for the treatment of VEGF-driven ocular diseases. Despite numerous attempts by industry and anonymous sources to discredit and prevent its use, bevacizumab spread globally owing to its availability; its low treatment cost, which was $5.50 per 1 mg in the United States; the evidence of efficacy based on OCT imaging and vision improvement; and its perceived safety. In the United States alone, the use of OCT-guided therapy and the use of bevacizumab for the treatment of exudative AMD has saved Medicare over $40 billion since 2008. CONCLUSIONS: The rapid adoption of OCT-guided therapy and the use of intravitreal bevacizumab by the global retinal community has prevented blindness from exudative and neovascular ocular diseases worldwide while saving healthcare providers and patients billions of dollars.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Rosenfeld PJ. Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture. Am J Ophthalmol. 2019. PMID: 30851267. doi:10.1016/j.ajo.2019.02.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。